The narrow promise of lecanemab for Alzheimer disease

Lecanemab arrived in Canada in January 2026 as an anti-amyloid therapy meant to slow Alzheimer disease. A new practice article in CMAJ , " Lecanemab use for early Alzheimer disease in Canada ," lays out key challenges with the drug including narrow eligibility, a modest effect that may not be clinically meaningful, and a resource-intensive path to treatment. Dr. Sophie Weiss, a co-author of the…